AstraZeneca debuts $300M cell therapy manufacturing facility in Maryland
AstraZeneca has achieved a cell therapy milestone by opening a manufacturing site in Rockville, Maryland. The $300 million plant will employ at least 150 staffers and produce clinical and potential commercial CAR-T treatments. The project forms part of AZ’s commitment to invest $3.5 billion in the U.S.
AstraZeneca has achieved a cell therapy milestone by opening a manufacturing site in Rockville, Maryland. The $300 million plant will employ at least 150 staffers and produce clinical and potential commercial CAR-T treatments. The project forms part of AZ’s commitment to invest $3.5 billion in the U.S.
